Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse p12 months from auto-SCT) and late relapse (either relapsed 412 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; Po0.001) and from auto-SCT (20.1 vs 82.5 months; Po0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (Po0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index X1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.
Introduction
Multiple myeloma accounts for nearly 10% of hematological and 1% of all malignancies in the United States and estimates for 2007 predict for 19 700 new cases and 12 000 deaths due to myeloma. 1, 2 Combination chemotherapy with melphalan and prednisone was the mainstay of therapy, with more intense multidrug regimens not improving the survival any further, 3, 4 until the introduction of high dose therapy and auto-SCT. Since then several randomized trials have demonstrated improved overall survival with auto-SCT, and subsequent trials demonstrating equivalent benefit with auto-SCT performed early or late in the course of disease. [5] [6] [7] However, not all trials have been able to demonstrate a survival advantage for auto-SCT in myeloma, and it is not clear if all or only a selected set of patients derive survival benefit from auto-SCT. [8] [9] [10] Nevertheless, auto-SCT performed early in the disease course, typically after four cycles of initial therapy, remains the most common approach in patients who are considered eligible to undergo the procedure. More recently, clinical trials incorporating novel therapies such as thalidomide and its analogs and the proteasome inhibitor bortezomib continue to redefine the role of auto-SCT in this new era. [11] [12] [13] [14] Early auto-SCT in patients with myeloma have typically resulted in median progression free survival of 2-3 years and overall survival of 4-5 years in randomized trials. [5] [6] [7] Various risk factors have been shown to identify patients with short survival after an auto-SCT, most importantly high risk genetic features. [15] [16] [17] [18] Although auto-SCT can result in sustained responses in a large proportion of patients, nearly a fifth of the patients relapse within a year after auto-SCT. Here, we present the outcome of these patients, following their relapse after auto-SCT.
Patients and methods
Four hundred and ninety four patients with multiple myeloma, who underwent stem cell collection and autologous transplantation between January 1994 and August 2006 were included for this study. Only patients who received their SCT within 12 months of the initial diagnosis of myeloma were included. Patients who were progression free at last visit required at least 12 months of follow up from SCT to be included in the study. Patients who proceeded to an allo-SCT following their relapse were censored at the time of their allo-SCT. Those receiving tandem auto-SCT were excluded from the current analysis. Patients were grouped into two categories; those relapsing early after high-dose therapy (o12 months) and those relapsing X12 months after transplant or those who have not relapsed at last follow up. Data pertaining to the transplant patients were captured prospectively into a database, which is continuously updated. Complete follow-up was available for all the patients. All patients provided written informed consent for use of their medical records. Approval from the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
The majority of the patients (193; 39.3%) were initially treated with dexamethasone alone at 40 mg/day on days 1-4, 9-12 and 17-20 of a 28-day treatment cycle. Nearly a quarter of the patients (130; 26.4%) initially received VCR, doxorubicin and dexamethasone (VAD) chemotherapy for four cycles as originally described. 19 One hundred nineteen patients (24.2%) had induction therapy with dexamethasone in combination with thalidomide, with the thalidomide either added initially or after the first cycle because of lack of response to dexamethasone alone. The dexamethasone was generally given at 40 mg/day on days 1-4, 9-12 and 17-20. In the combination therapy, thalidomide was given at varying doses of 100-400 mg/day as tolerated. Twenty-six patients received lenalidomide and dexamethasone as their initial therapy, and the remaining twenty-six patients had other regimens including VCR, carmustine, melphalan, cyclophosphamide and prednisone (VBMCP).
After the completion of initial therapy, stem cells were collected using G-CSF priming alone in 219 patients (44.3%). G-CSF was administered subcutaneously (10 mg/kg) daily until the completion of peripheral blood stem cell collection with apheresis beginning on the fifth day after starting G-CSF. The remaining 275 (55.7%) patients had stem cells collected after administration of cyclophosphamide 1.5 g/m 2 per day for 2 consecutive days, followed by G-CSF at 10 mg/kg starting on day 3 and continuing through the period of granulocytopenia.
Since June 2000, the standard conditioning regimen has been melphalan given at 200 mg/m 2 divided over 2 days. Forty-four patients (10.2%) prior to this date received melphalan at 140 mg/m 2 on day À4, followed by total body radiation of 2 Gy twice daily on days À3 to À1. Three hundred ninety five patients (80.1%) underwent conditioning with melphalan alone, usually given at 200 mg/m 2 given either as a single dose on day À1 or split over two days (100 mg/m 2 days À2 and À1). In forty-seven patients (9.5%) melphalan was dose reduced to 100-140 mg/m 2 because of advanced age, renal insufficiency or poor performance status.
Standard response criteria were used except that BM biopsy was not consistently performed to confirm a CR. CR was defined as lack of detectable monoclonal (M) protein in serum and urine by immunoelectrophoresis and immunofixation. Relapse or progression was defined as a 50% increase in the serum M-protein or 24-h urinary M-protein excretion over the lowest remission level. In those patients who achieve a CR, any detection of M-protein by immunofixation, increase in the size of existing lytic bony lesions or soft-tissue plasmacytomas or appearance of new lytic bony lesions constituted relapse (or progression), even if not accompanied by measurable changes in the M-protein. BM plasma cell labeling index (PCLI), cytogenetics, b2-microglobulin and other laboratory variables were assessed pre-transplantation. Labeling index (a measure of the cell proliferation) is determined using a slide-based immunoflourescence method on BM samples, as described previously 20 and is classified as high when X1%.
The w 2 and Fisher exact tests were used to compare differences between nominal variables and the MannWhitney U-test or Kruskal-Wallis test were used for continuous variables. Kaplan-Meier analysis was used for analyzing overall and progression free survival. Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. 21 Time to progression was measured as time from transplantation to disease progression, with those dying without evidence of relapse censored at the time of death. Overall survival was defined as the time from transplantation or from the date of initial diagnosis of myeloma to the date of death or last follow-up, as the case may be. Multivariate analysis was performed using logistic regression using relapse by 12 months as the endpoint. 22 
Results
Four hundred and ninety four patients, who underwent auto-SCT within 12 months of diagnosis, were studied. The median estimated follow-up for the entire group from diagnosis and auto-SCT was 49 months (95% CI; 45, 54) and 43 months (95% CI; 39, 47), respectively. Three hundred and forty five patients (70%) have relapsed after auto-SCT and the median estimated follow-up from relapse was 27 months (95% CI; 24, 30) for these patients.
Baseline characteristics
This study cohort of 494 patients was followed prospectively and analyzed on the basis of early or late relapse as defined above. The baseline characteristics of these two groups are summarized in Table 1 . One hundred twenty patients (24%) were in the early relapse group whereas the remaining 374 (76%) were in the late relapse group, of whom 225 patients had relapsed and the remaining 149 patients were progression-free at the time of last visit. No statistically significant differences were noted for age at diagnosis or transplant, M-protein level, BM plasma cell percentage, lactate dehydrogenase (LDH), creatinine, gender, stage, b 2 M (b 2 -microglobulin) level, presence of bone disease or immunoglobulin subtype involved. The difference in PCLI between the two groups reached statistical significance with 39% of patients in the early relapse group compared to 15.7% of patient in the late relapse group having an elevated PCLI (Po0.001). Additionally, patients with early relapse had a higher percentage of abnormal cytogenetics 29.3 vs 14.6% (Po0.001) and a higher percentage of circulating plasma cells at stem cell collection with 49.6 vs 32.6% (P ¼ 0.008) when compared to the late relapse group. Early relapse patients were more likely to have had relapsed/refractory disease at the time of transplant compared to their late relapse counterparts (40 vs 26.7 P ¼ 0.03). In addition, 19.3% of patients in the early relapse group had received more than one regimen prior to SCT compared to 7.3% among the rest (P ¼ 0.006).
Transplant outcomes
The median overall survival from diagnosis and from transplant for the entire cohort was 71.0 months (95% CI; 62, 81) and 65.5 months (95% CI; 56, 75), respectively. The median time to progression from transplant for the entire cohort was 22.1 months (95% CI; 20, 25). Median overall survival from diagnosis was 26.6 months (95% CI; 23, 31) in the early relapse group compared to 90.7 months (95% CI; 71, 111) in the late relapse group (Po0.001; Figure 1a ). Overall survival from transplant was 20.1 months (95% CI; 17, 23) in the early relapse group compared to 82.5 months (95% CI; 63, 102) for the late relapse group (Po0.001). Finally, among the 345 patients who had disease progression after transplant, overall survival from relapse was 10.8 (95% CI; 9, 13) months for the early relapse group compared to 41.8 months (95% CI; 37, 47) for the late relapse group (Po0.001; Figure 1b) . The overall survival following relapse was longer with increasing duration of response to the SCT (Figure 2a ). The distribution of survival times from diagnosis for the patients relapsing after SCT is as in Figure 2b . Among the 97 patients who relapsed early after transplant, we examined if subsequent exposure to one of the novel agents (thalidomide, bortezomib and lenalidomide) had any impact on the outcome. The median survival from the time of relapse for the 70 patients who were treated with at least one of the new drugs following their relapse after SCT was 15.9 months (95% CI; 13, 18) compared to 4.5 months (95% CI; 2, 7) for the 27 patients not treated with at least one of the new drugs (Po0.01; Figure 3 ).
Given the strong prognostic value of cytogenetic features such as deletion 13, t(4;14) and p53 abnormalities on the outcome after auto-SCT, we examined early relapse as a prognostic factor in the context of these variables in a smaller data set. The 215 patients in this data set were evaluated for these abnormalities in a retrospective fashion using archived samples as part of a different study, which has been published previously. 16 The presence of any of these three abnormalities (del13, 17p-or t(4;14)) by FISH predicted for a shorter overall survival from relapse; 10.3 months in the presence of one or more abnormalities vs 20.8 months in their absence (Po0.01). In a multivariate model that included presence of one of these abnormalities and time to relapse from auto-SCT, only relapse with in 12 months of auto-SCT was associated with a higher hazard of death post relapse; Po0.01. Multivariate models incorporating presence or absence of either one of the three abnormalities as a variable along with early relapse also demonstrated independent significance for early relapse.
Risk factors for early relapse (relapse within 12 months)
A univariate analysis was performed to identify risk factors predicting relapse within 12 months following auto-SCT. In this analysis, marrow plasma cells 430% at transplant, labeling index (PCLI) 41% at transplant, any abnormal cytogenetics, greater than one regimen prior to SCT, relapsing disease at the time of SCT, presence of circulating plasma cells at the time of stem cell collection and inability to achieve a CR after auto-SCT, all predicted for relapse within 12 months. In a multivariate analysis using these factors, only an elevated PCLI (41%) at transplant, greater than one treatment regimen prior to SCT, and failure to achieve a CR were predictive of relapse within 12 months of SCT (Table 2) . Prognostic factors for overall survival from auto-SCT were then examined using Cox Proportional Hazards model. On univariate analysis, relapse within 12 months of auto-SCT, more than one treatment regimen prior to SCT, b 2 M 45.5 mcg per 100 ml, BM plasma cells 430%, PCLI 4 ¼ 1%, abnormalities on conventional cytogenetics, circulating plasma cells at the time of stem cell harvest (measured by immunoflourescence Early relapse after HDT for myeloma S Kumar et al microscopy) and failure to achieve a CR from SCT were all risk factors for shorter overall survival post SCT. In multivariate model that included these risk factors, relapse within 12 months of auto-SCT, PCLI 4 ¼ 1% and b 2 M 45.5 mcg per 100 ml were prognostic for overall survival after SCT (Table 3) .
Discussion
Auto-SCT remains an effective therapy for multiple myeloma with median progression free interval of 2-3 years. The prospect of improved quality of life without symptoms and toxicity from ongoing therapy remain the most compelling indications for this approach. [5] [6] [7] However, nearly a fifth of the patients undergoing stem cell transplant have disease progression within a year. As shown in the current study these patients have a particularly poor outcome, with median survival of 10.8 months from the time of relapse. Identification of genetic abnormalities such as t(4:14), t(14:16), p53 (17p-) abnormalities, chromosome 13 abnormalities on conventional cytogenetics clearly predict for poor outcome in the majority of patients with these abnormalities. 15, [23] [24] [25] [26] In addition, a host of other high risk features have been identified in myeloma including presence of proliferating myeloma cells as measured by labeling index, higher International Staging System stage, plasmablastic morphology and high LDH among others. 17, 24, [27] [28] [29] [30] Previous studies have demonstrated poor survival among patients with some of these poor genetic risk factors undergoing SCT whereas others have suggested a reduced impact of these markers in the absence of an elevated b 2 M. 31 Although recognition of some of these high risk features may dissuade patients and physicians from proceeding to auto-SCT, many patients without these abnormalities have myeloma that relapse shortly after SCT.
In the current study, the outcome of patients relapsing early after SCT was compared to those with longer duration of benefit from SCT. In the current study, we excluded patients who received a delayed SCT, as these patients typically have a shorter response duration compared to those transplanted early in the disease course. Although the overall survival from transplant would be expected to be longer from SCT with increasing duration of response, the short median survival from the time of relapse in those relapsing within a year of SCT compared to those relapsing after longer response duration reflects aggressive disease biology. This is further supported by the observation of increasing survival from relapse with increasing duration of response to the SCT. The result presented here confirms previous observations regarding duration of response after first SCT. [32] [33] [34] Clearly these patients derive little benefit from conventional salvage therapies, to which they become resistant rapidly, as highlighted by the median survival of only 10.8 months from the time they relapse. It is interesting that patients who were treated with at least one of the novel agents (thalidomide, bortezomib or lenalidomide) appeared to have some improvement in their median survival post transplant; 15 months vs 5 months for the rest. Clearly, this might also reflect improvements in supportive care over the past decade as those who were exposed to the new drugs would have been transplanted in more recent times. Additionally, this might also reflect selection of patients with relatively better biology from among this poor risk group of patients, as patients living longer after relapse are more likely to have had the opportunity to receive the new agents. Also, patients with a poor functional status are not likely to be enrolled on the clinical trials of new agents. Even though the survival of those receiving the newer drugs appeared improved, it is still vastly inferior to the remaining patients, underscoring the urgent need for better therapeutic strategies. The aggressive biology of these patients are to some extent 
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No new agents (n=50) Proportion surviving Figure 3 Kaplan-Meier curves demonstrating the overall survival from the time of relapse among 120 patients who relapsed early (o12 months from SCT). Patients who were not exposed to any of the newer agents have an inferior overall survival (Po0.01). Early relapse after HDT for myeloma S Kumar et al explained on the basis of abnormal cytogenetics features as highlighted in Table 1 , with nearly a third of these patients having cytogenetic abnormalities and as expected higher labeling index reiterating the relationship between presence of proliferating cells and likelihood of detecting metaphase abnormalities. However, these alone do not explain the outcome of the patients relapsing early, as early relapse was independently predictive of short overall survival post transplant when examined along with many of the known risk factors. Clearly, early relapse after upfront SCT for myeloma should be recognized as a novel poor risk factor in patients with myeloma and these patients should be counseled on their prognosis and should be considered for novel approaches through clinical trials. A recent subgroup analysis of a phase III trial of bortezomib and pegylated doxorubicin demonstrated significant improvement in the overall survival among the early relapse patients compared to bortezomib alone. 35 This data suggests the need for approaching these patients with combination regimens that incorporate new and old agents with different mechanisms of action. Younger patients can be considered for allogeneic approaches early on, preferably in the setting of a clinical trial, given the current controversy regarding survival benefit with this approach. 36, 37 The analysis of the risk factors predicting an early relapse after SCT can be a helpful guide while making treatment decisions for these patients. In the current study, presence of a high labeling index and the patients with relapsing disease at the time of SCT had a higher risk of early relapse, as did a failure to achieve CR after SCT. Achievement of CR or very good partial response (VGPR) has been recognized in multiple studies to be a predictor of improved response duration and overall survival following SCT. We have previously described a high plasma cell proliferative rate to be an adverse prognostic factor for outcome in myeloma, and the results from the current study also likely reflect the higher proportion of active disease in that group at the time of SCT. Similarly, patients who were relapsing from initial therapy at the time of SCT also were at a higher risk of early relapse, likely reflecting rapid development of drug resistance and high-risk biology. We have previously shown that lack of response to initial therapy of the disease does not preclude a comparable outcome from SCT. 38 Data presented here does not necessarily contradict previous findings as other studies have demonstrated an inferior outcome for those patients among the primary refractory patients, who have disease that is truly progressive on the face of initial therapy. 39 It is possible that these patients share similar biological characteristics such as high proliferative potential and innate drug resistance. Although this latter group of patients may not gain much from an auto-SCT approach, patients with primary refractory disease that is not progressive on therapy will benefit from an auto-SCT. In patients not achieving a CR post SCT, maintenance approaches should be given strong consideration, especially in light of prospective data showing a benefit in this group for maintenance thalidomide. 40 The benefit of a tandem approach in this group of patients were not specifically addressed, but several randomized trials have shown an event free and overall survival benefit for tandem approaches in patients failing to achieve a very good partial response to the first autograft. 41 Presence of cytogenetic abnormalities did not come out as a significant factor in the multivariate analysis and likely reflects the limitations of conventional cytogenetic analysis in myeloma. Given the time span over which these patients were treated, we do not have FISH data on all the patients. However, analysis of a subgroup of transplanted patients in whom FISH data was available demonstrates that the prognostic value of early relapse after auto-SCT is independent of these variables. This is not surprising as significant heterogeneity exists among the outcome of patients with abnormalities such as t (4;14) as demonstrated by the relatively good outcome among patients with t(4;14) with low b 2 M and high hemoglobin as demonstrated in a recent study. 31 It is likely that the phenomenon of early relapse is a better indicator of the functional significance of these prognostic factors and is able to provide us with a composite of the multiple prognostic variables.
The result of the current study serves to highlight the inferior outcome of patients relapsing early after SCT. These patients should be considered high-risk patients and should be considered for clinical trials examining novel treatment combinations that incorporate multiple agents with different mechanisms or clinical trials of allogeneic approaches, even in the absence of other conventional risk factors. The survival data presented here can be considered as a reference point for trials aimed at improving the survival of this group of patients.
